Spero Therapeutics (SPRO) Reports Complete Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem - StreetInsider.com

Spero Therapeutics (SPRO) Reports Complete Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem  StreetInsider.com

Comments

Popular posts from this blog

Summary of Society for Maternal-Fetal Medicine (SMFM) Consult Series #52: Diagnosis and management of fetal growth restriction - Contemporary Obgyn

Sarcoidosis: Causes, Symptoms, Diagnosis & Treatment

BTS Clinical Statement on air travel for passengers with respiratory disease - Thorax (BMJ)